NASDAQ:NLSP - NLS Pharmaceutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.64
▲ +0.01 (1.59%)

This chart shows the closing price for NLSP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NLS Pharmaceutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NLSP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NLSP

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NLS Pharmaceutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $0.64.

This chart shows the closing price for NLSP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in NLS Pharmaceutics. This rating has held steady since February 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2021Brookline Capital AcquisitionInitiated CoverageBuy$12.00Low
3/12/2021Brookline Capital ManagementInitiated CoverageBuy$12.00High
3/9/2021Maxim GroupInitiated CoverageBuy$8.00Low
3/3/2021Maxim GroupInitiated CoverageBuy$8.00High
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/26/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/25/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2022
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/25/2022

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
NLS Pharmaceutics logo
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
Read More

Today's Range

Now: $0.64
Low: $0.59
High: $0.69

50 Day Range

MA: $1.00
Low: $0.57
High: $1.44

52 Week Range

Now: $0.64
Low: $0.55
High: $3.73

Volume

52,527 shs

Average Volume

1,973,924 shs

Market Capitalization

$7.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of NLS Pharmaceutics?

The following equities research analysts have issued research reports on NLS Pharmaceutics in the last year: Zacks Investment Research.
View the latest analyst ratings for NLSP.

What is the current price target for NLS Pharmaceutics?

0 Wall Street analysts have set twelve-month price targets for NLS Pharmaceutics in the last year.
View the latest price targets for NLSP.

What is the current consensus analyst rating for NLS Pharmaceutics?

NLS Pharmaceutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NLSP.

How do I contact NLS Pharmaceutics' investor relations team?

NLS Pharmaceutics' physical mailing address is ALTER POSTPLATZ 2, STANS V8, CH-6370. The company's listed phone number is 41-42-000-0000. The official website for NLS Pharmaceutics is www.nlspharma.com. Learn More about contacing NLS Pharmaceutics investor relations.